-+ 0.00%
-+ 0.00%
-+ 0.00%
BioNTech's US stock fell about 10% before the market, and the company announced the termination of phase II clinical trials for colorectal cancer.
Share
Listen to the news
BioNTech's US stock fell about 10% before the market, and the company announced the termination of phase II clinical trials for colorectal cancer.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending